38025-34-2

Basic information

• Product Name: 4-ethyl-1,2,3,6-tetrahydro-1-(phenylmethyl)Pyridine
• Synonyms: 4-ethyl-1,2,3,6-tetrahydro-1-(phenylmethyl)Pyridine
• CAS NO: 38025-34-2
• Molecular Weight: 201.312
• Mol File: 38025-34-2.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 4-ethyl-1,2,3,6-tetrahydro-1-(phenylmethyl)Pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ethyl-1,2,3,6-tetrahydro-1-(phenylmethyl)Pyridine(38025-34-2)
• EPA Substance Registry System: 4-ethyl-1,2,3,6-tetrahydro-1-(phenylmethyl)Pyridine(38025-34-2)

Safety Data

• Hazardous Substances Data: 38025-34-2(Hazardous Substances Data)

Upstream product

• 79094-67-0 1-benzyl-4'-ethylpyridinium bromide 
• 50-00-0 formaldehyd 
• 97-94-9 triethyl borane 
• 70882-08-5 N-benzylbuta-2,3-dien-1-amine 
• 107301-61-1 N-benzyl-4-amino-1-butyne 
• 536-75-4 4-Ethylpyridine 
• 100-39-0 benzyl bromide 

Downstream Products

• 3230-23-7 4-ethylpiperidine 

Relevant articles and documents

Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic)

Past studies have shown that it has been difficult to discover and develop potent and selective κ opioid receptor antagonists, particularly compounds having potential for clinical development. In this study, we present a structure-activity relationship (SAR) study of a recently discovered new class of tetrahydroisoquinoline κ opioid receptor antagonists which led to (3R)-7-hydroxy-N-{(1S)-2-methyl-1-[(-4-methylpiperidine-1-yl)methyl]propyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (12) (4-Me-PDTic). Compound 12 had a Ke = 0.37 nM in a [35S]GTPγS binding assay and was 645- and >8100-fold selective for the κ relative to the μ and δ opioid receptors, respectively. Calculated log BB and CNS (central nervous system) multiparameter optimization (MPO) and low molecular weight values all predict that 12 will penetrate the brain, and pharmacokinetic studies in rats show that 12 does indeed penetrate the brain.

Palladium(0)-catalyzed alkynyl and allenyl iminium ion cyclizations leading to 1,4-disubstituted 1,2,3,6-tetrahydropyridines

(Chemical Equation Presented) The biologically important title heterocyclic compounds can be synthesized by two methods based on the cyclization of alkynyl and allenyl iminium ions generated in situ in the presence of organometallic reagents (see scheme).

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to alkyne compounds of general formula I wherein the groups and radicals A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one alkyne according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.